您的位置: 首页 > 2015年3月 第46卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

D-二聚体及纤维蛋白原在社区获得性肺炎严重程度评估中的应用价值

Plasma D-dimer and fibrinogen for stratification of severity of community acquired pneumonia

来源期刊: 广州医药 | 39-40 发布时间:2021-11-30 收稿时间:2025/11/13 16:48:59 阅读量:26
作者:
关键词:
D-二聚体纤维蛋白原社区获得性肺炎严重程度
D-dimerFibrinogenCommunity acquired pneumoniaSeverity
DOI:
10.3969/j.issn.1000-8535.2015.02.013
收稿时间:
2014-11-11 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨血浆D-二聚体及纤维蛋白原在社区获得性肺炎患者严重程度评估的应用价值。方法 收集110例社区获得性肺炎患者的临床资料,根据CURB-65评分标准对患者进行分组,分别测定患者血浆D-二聚体及纤维蛋白原水平,比较其在不同分组间的差异及通过ROC曲线了解其在重症社区获得性肺炎诊断中的价值。结果 不同CURB-65分组间D-二聚体、纤维蛋白原水平比较差异有统计学意义(P<0.05),重症肺炎组D-二聚体、纤维蛋白原水平明显高于非重症肺炎组(P<0.05)。ROC曲线显示入院D-二聚体、纤维蛋白原水平诊断重症肺炎曲线下面积(AUC)分别为0.815、0.777。结论 血浆D-二聚体及纤维蛋白原可以有效评估社区获得性肺炎患者病情的严重程度,其是诊断重症肺炎的一个良好指标。
Objective To evaluate the prediction and evaluation of plasma D-dimer and fibrinogen levels upon the severity of community acquired pneumonia(CAP). Methods Clinical variables of 180 patients with CAP were evaluated and divided into different groups by CURB65.Plasma D-dimer and fibrinogen were measured to compare their levels among different groups and evaluate the prediction in the diagnosis of the severe CAP by ROC curve. Results The mean D-dimer and fibrinogen level were different significantly among different CURB65 groups. D-dimer and fibrinogen level of severe CAP were significantly higher than non-serious pnrumonia group. The area under the curve of the D-dimer, fibrinogen in the diagnosis of severe pneumonia were 0.815, 0.777. Conclusion Plasma D-dimer and fibrinogen can effectively evaluate the severity of illness in patients with community acquired pneumonia and they could be useful for assessment of the severity of CAP.
1、 沈国忠,李海金,沈建英,等.凝血功能与社区获得性肺炎严重程度的关系[J].中国现代医生,2014,52(12):48-50. 沈国忠,李海金,沈建英,等.凝血功能与社区获得性肺炎严重程度的关系[J].中国现代医生,2014,52(12):48-50.
2、 Snijders D, Schoorl M, Bartels PC, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial[J]. Eur J Intern Med, 2012, 23(5):436-441. Snijders D, Schoorl M, Bartels PC, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial[J]. Eur J Intern Med, 2012, 23(5):436-441.
3、 庄其宏,曾奕明,史永红.社区获得性肺炎凝血功能异常对预后的影响[J].中华结核和呼吸杂志,2014,37(6):406-410. 庄其宏,曾奕明,史永红.社区获得性肺炎凝血功能异常对预后的影响[J].中华结核和呼吸杂志,2014,37(6):406-410.
4、 戴林峰,王醒.脓毒症与凝血功能异常[J].东南大学学报(医学版),2012,31(3):359-362. 戴林峰,王醒.脓毒症与凝血功能异常[J].东南大学学报(医学版),2012,31(3):359-362.
5、 Sligl WI, Marrie TJ:Severe community-acquired pneumonia[J]. Crit Care Clin, 2013, 29(3):563-601. Sligl WI, Marrie TJ:Severe community-acquired pneumonia[J]. Crit Care Clin, 2013, 29(3):563-601.
6、 Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2007(44 Suppl 2):S27-72. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2007(44 Suppl 2):S27-72.
7、 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006(10):651-655. 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006(10):651-655.
8、 Lim WS, Van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study[J]. Thorax, 2003, 58(5):377-382. Lim WS, Van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study[J]. Thorax, 2003, 58(5):377-382.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录